Bio/Pharma Capital Expenditure (CapEx) Trends – 2019 PharmSource Edition
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Capital expenditure by mega cap pharma companies has rapidly increased with investments in biologic API production. In recent years, the largest public companies have heavily invested in biologic and injectable capabilities. The increasing amount of large pharma CapEx projects involving both active pharmaceutical ingredient (API) biologics (protein and peptide) and injectable manufacturing is influenced both by the shift of the drugs pipeline to biologics and to the lucrative nature of biologic and high-potency injectable sales.
This expert trend report is a comprehensive look at the capital expenditure of pharma companies on manufacturing facilities/capabilities, including analysis of market cap patterns, headquarter geography and manufacturing services being invested in. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management.
Scope
This 32-page report gives an important expert quantitative analysis on the capital expenditure. Findings are based on the GlobalData’s Financial Analytics tool, financials have been analyzed for 1,345 pharma companies. The 5 tables and 11 figures throughout the report illustrate major points and trends.
This report is required reading for –
- CMO executives and strategic decision-makers: improves understanding of the dose CMO industry and a critical input for strategic planning efforts.
- Sourcing and procurement executives in bio/pharmaceutical companies: improving understanding of crucial components of the supply base that will provide insights for supplier selection and management.
- Suppliers of capital components
Reasons to Buy
Buy this report to answer these key questions:
- How are trends in CapEx related to company revenue?
- What has been the CapEx growth trends between 2014-2018?
- How do trends in CapEx vary by company market cap?
- How do CapEx trend change by company HQ location?
- What is the CapEx for leading public CDMOs?
- Which pharma companies have the highest number of CapEx projects?
- What CapEx projects were completed 2016–2018 or have a projected completion for 2019–2025 and which manufacturing services and facility locations are involved?
Alexion Pharmaceuticals Inc
Amgen Inc
Astellas Pharma Inc
AstraZeneca Plc
Bachem Holding AG
Bayer AG
Biogen Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cambrex Corp
Catalent Inc
Chugai Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Dottikon ES Holding AG
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Fresenius
GlaxoSmithKline Plc
Johnson & Johnson
Lonza Group Ltd
Merck & Co Inc
Novartis AG
Novo Nordisk AS
Otsuka Holdings Co Ltd
Pfizer Inc
Recipharm AB
Sanofi
Siegfried Holding AG
Sumitomo Dainippon Pharma Co Ltd
Syngene International Ltd
Takeda Pharmaceutical Co Ltd
Teva Pharmaceutical Industries Ltd
UCB SA
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.